EZH2 mutations are frequent and represent an early event in follicular lymphoma

Blood

Volumn 122, Issue 18, 2013, Pages 3165-3168

  Bödör, Csaba ^a,b   Grossmann, Vera ^c,d   Popov, Nikolay ^a   Okosun, Jessica ^a   O’Riain, Ciarán ^a   Tan, King ^e   Marzec, Jacek ^a   Araf, Shamzah ^a   Wang, Jun ^a   Lee, Abigail M ^a   Clear, Andrew ^a   Montoto, Silvia ^a   Matthews, Janet ^a   Iqbal, Sameena ^a   Rajnai, Hajnalka ^b   Rosenwald, Andreas ^f   Ott, German ^f,g   Campo, Elias ^h   Rimsza, Lisa M ⁱ   Smeland, Erlend B ^j,k   Chan, Wing C ^l   Braziel, Rita M ^m   Staudt, Louis M ⁿ   Wright, George ⁿ   Lister, T Andrew ^a   Elemento, Olivier ^o   Hills, Robert ^p   Gribben, John G ^a   Chelala, Claude ^a   Matolcsy, András ^b   Kohlmann, Alexander ^c   Haferlach, Torsten ^c   Gascoyne, Randy D ^e   Jude, Fitzgibbon ^a   more..

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f UNIVERSITY OF WÜRZBURG   (Germany)

^g DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^h UNIVERSITY OF BARCELONA   (Spain)

ⁱ UNIVERSITY OF ARIZONA   (United States)

^j OSLO UNIVERSITY HOSPITAL   (Norway)

^k UNIVERSITY OF OSLO   (Norway)

^l UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^m OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁿ NATIONAL CANCER INSTITUTE   (United States)

^o WEILL CORNELL MEDICAL COLLEGE   (United States)

^p CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; TRANSCRIPTION FACTOR EZH2; CREBBP PROTEIN, HUMAN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; EZH2 PROTEIN, HUMAN; HERPESVIRUS ENTRY MEDIATOR; MEF2B PROTEIN, HUMAN; MYOCYTE ENHANCER FACTOR 2; POLYCOMB REPRESSIVE COMPLEX 2; TNFRSF14 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER INCIDENCE; CONTROLLED STUDY; DISEASE COURSE; FOLLICULAR LYMPHOMA; GAIN OF FUNCTION MUTATION; GENE FREQUENCY; GENETIC VARIABILITY; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MUTATION RATE; PRIORITY JOURNAL; SANGER SEQUENCING; COHORT ANALYSIS; GENE EXPRESSION PROFILING; GENETICS; KAPLAN MEIER METHOD; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; TIME;

COHORT STUDIES; CREB-BINDING PROTEIN; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION PROFILING; GENE FREQUENCY; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, FOLLICULAR; MEF2 TRANSCRIPTION FACTORS; MUTATION; POLYCOMB REPRESSIVE COMPLEX 2; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 14; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84891603187     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-04-496893     Document Type: Article

References (24)

1. Pasqualucci L, Dominguez-Sola D, Chiarenza A, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 2011; 471(7337):189-195.
2. Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476(7360): 298-303.
3. Viré E, Brenner C, Deplus R, et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature. 2006;439(7078):871-874.
4. Bödör C, O’Riain C, Wrench D, et al. EZH2 Y641 mutations in follicular lymphoma. Leukemia. 2011; 25(4):726-729.
5. Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010;42(2): 181-185.
6. Sneeringer CJ, Scott MP, Kuntz KW, et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci USA. 2010; 107(49):20980-20985.
7. Yap DB, Chu J, Berg T, et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood. 2011;117(8):2451-2459.
8. Ryan RJ, Nitta M, Borger D, et al. EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas. PLoS ONE. 2011;6(12):e28585.
9. Lohr JG, Stojanov P, Lawrence MS, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci USA. 2012;109(10):3879-3884.
10. Majer CR, Jin L, Scott MP, et al. A687V EZH2 is a gain-of-function mutation found in lymphoma patients. FEBS Lett. 2012;586(19):3448-3451.
11. McCabe MT, Graves AP, Ganji G, et al. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc Natl Acad Sci USA. 2012;109(8): 2989-2994.
12. Creasy CL. A novel selective EZH2 inhibitor exhibits anti-tumor activity in lymphoma with EZH2 activating mutations. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research, March 31-April 4, 2012 Chicago, IL; Philadelphia, PA: AACR; 2012:492.
13. McCabe MT, Ott HM, Ganji G, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012; 492(7427):108-112.
14. Qi W, Chan H, Teng L, et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci USA. 2012; 109(52):21360-21365.
15. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351(21):2159-2169.
16. Grossmann V, Kohlmann A, Eder C, et al. Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in .80% of patients with TET2 and EZH2 being of high prognostic relevance. Leukemia. 2011;25(5): 877-879.
17. Kohlmann A, Klein HU, Weissmann S, et al. The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories. Leukemia. 2011;25(12):1840-1848.
18. Bachmann N, Hoegel J, Haeusler J, et al. Mutation screen and association study of EZH2 as a susceptibility gene for aggressive prostate cancer. Prostate. 2005;65(3):252-259.
19. Van Loo P, Nilsen G, Nordgard SH, et al. Analyzing cancer samples with SNP arrays. Methods Mol Biol. 2012;802:57-72.
20. Wrench D SA, Tayyib H, Kang MK, et al. TNFRSF14 and EZH2 mutations, Chr2p gain and copy number changes targeting genes whose proteins interact with the microenvironment. In: Transformed follicular lymphoma. ASH meeting abstract. 2010.
21. Cheung KJ, Johnson NA, Affleck JG, et al. Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis. Cancer Res. 2010;70(22):9166-9174.
22. O’Shea D, O’Riain C, Gupta M, et al. Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation. Blood. 2009;113(10):2298-2301.
23. O’Riain C, O’Shea DM, Yang Y, et al. Array-based DNA methylation profiling in follicular lymphoma. Leukemia. 2009;23(10):1858-1866.
24. Green MR, Gentles AJ, Nair RV, et al. Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood. 2013;121(9):1604-1611.